CN1120832A - 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 - Google Patents
涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 Download PDFInfo
- Publication number
- CN1120832A CN1120832A CN94191734A CN94191734A CN1120832A CN 1120832 A CN1120832 A CN 1120832A CN 94191734 A CN94191734 A CN 94191734A CN 94191734 A CN94191734 A CN 94191734A CN 1120832 A CN1120832 A CN 1120832A
- Authority
- CN
- China
- Prior art keywords
- coating
- spc
- sodium percarbonate
- peroxide
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
- C01B15/106—Stabilisation of the solid compounds, subsequent to the preparation or to the crystallisation, by additives or by coating
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/39—Organic or inorganic per-compounds
- C11D3/3942—Inorganic per-compounds
Abstract
过碳酸钠通常以涂敷颗粒形式使用,以增加其在洗涤剂中的贮存稳定性。根据本发明涂敷的过碳酸钠颗粒的涂层含有四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应的产物。涂敷过碳酸钠颗粒通过将上述反应产物的溶液涂敷到过碳酸盐颗粒上来制备。含有根据本发明涂敷的过碳酸钠颗粒的洗涤剂、漂白剂和清洁剂组合物具有很高的贮存稳定性。
Description
本发明涉及涂敷的过碳酸钠颗粒,其涂层含过氧化的硼化合物,它赋予过碳酸钠高的贮存稳定性。本发明也涉及生产该涂敷的过碳酸钠颗粒的方法,通过将一种或多种涂层组分,尤其以其水溶液形式涂敷到待涂敷的过碳酸钠上及涂敷到含有根据本发明的涂敷的过碳酸钠颗粒的洗涤剂、清洁剂及漂白剂组合物中。
过碳酸钠(2Na2CO3.3H2O2)在洗涤剂、漂白剂及清洁制剂中用做活性氧组分。考虑到过碳酸钠在潮湿环境中及在洗涤剂、清洁制剂中各种组分的存在下的贮藏稳定性差,必须提高过碳酸钠的稳定性以减少活性氧(Oa)的损失。稳定化的主要方法是将过碳酸钠颗粒涂敷上一层稳定组分。如已有的将过碳酸钠涂敷上石蜡或聚乙二醇。但遗憾的是,这种方法不仅使其在水中的溶解度大大降低,而且也不能获得足够长期的稳定性。即使碱金属硅酸盐涂敷到过碳酸钠的颗粒上,正如DE—OS 2652776中建议的,也不能达到足够的稳定性,另外还引入了不需要的不溶性组分。在DE—OS2417572和DE—OS 2622610所述的方法中,用硫酸钠和碳酸钠或硫酸钠、碳酸钠和硅酸钠做涂层组分。在这些方法中,将涂层组分的溶液喷洒在流化床干燥塔中的过碳酸钠颗粒上。获得足够的稳定性需要大量的涂敷物,从而相应使活性氧含量大大降低。
尽管从DE—PS 2800 916中了解到,含有偏硼酸、原硼酸和四硼酸中至少一种硼化合物的涂敷物能用于稳定过碳酸钠,但是,正如比较实施例中所示的DE—OS 3321082中把用这种方法获得的稳定效果看成是不够。然而,具有含硼酸钠的壳层的过碳酸钠被认为是有有利的。但是,正如本申请书的发明人在重复DE—OS33 21082的实施例时所发现的,为了获得足够的稳定性,硼酸盐及非必须的其它涂敷物组分不得不大量地存在于涂层中,以致使得以稳定的过碳酸钠的有效活性氧含量总是低于14wt%。在EP—A 0487256中进一步发展了使用硼酸盐的稳定化方法,尽管这里公开的涂敷方法至少包括两步,所以在技术上是复杂的。
最后,DE—AS 2458326中描述了一种稳定过碳酸钠的方法,即使是它与清洁剂掺和的情况下该方法也能提高纯过碳酸钠的贮存稳定性。在该法中,用加有过硼酸钠粉末的憎水有机化合物液涂敷过碳酸钠。该方法的弊端在于:为使工艺易于操作,作用的这种憎水液态有机化合物需要用低级醇稀释。另外,涂敷化合物的使用量十分高,即按过碳酸钠计5~20wt%的过硼酸钠和5~10wt%的憎水有机化合物。
DE—PS 2651442中介绍的涂敷过碳酸钠颗粒由过碳酸钠核及通式为NaBO2·H2O2·nH2O的过硼酸钠涂层构成,其中n小于3。按照DE—PS 2712139,涂层还可以含硅酸钠和其它加水粘合的物质。为了生产上述涂敷过碳酸钠颗粒,首先将过碳酸钠用水或硅酸钠水溶液湿润,水或溶液的用量极少以使过硼酸钠不至于转化成四水化合物,随后将湿润的过碳酸钠涂敷上一层无水过硼酸钠。DE—PS 2810379中介绍了上述方法的进一步改进,其中包括将过硼酸钠水溶液和硅酸钠溶液在40~60℃下喷洒在过碳酸钠上,其中过硼酸钠水溶液浓度为每升溶液中含50~500g四水过硼酸钠,然后全部或部分地除去过碳酸钠颗粒上引入的水份。
如迄今未出版的德国专利申请P 4306399.3中公开的,上述方法可以相当程度地得到简化,即在固/液分离器中部分分离湿法生产过碳酸钠产生的母液后,用过硼酸钠(NaBO2·H2O2)溶液冲洗上述湿法生产的过碳酸钠。尽管所需的涂敷物量很少,但在过碳酸钠的贮存中可以获得高的活性氧稳定性,这种过碳酸钠与典型的含沸石的洗涤剂塔粉混和。
含一水或四水过硼酸盐的涂敷物优于含硼酸盐或硼酸的过碳酸钠涂敷物,前者几乎不影响过碳酸钠颗粒中活性氧含量。
本发明论述的问题是使用新型含过氧的硼化合物进一步提高过碳酸钠的稳定性,并且提供了新型的涂敷的过碳酸钠颗粒,在相同的硼含量下,该颗粒比已知的有过硼酸盐涂层的过碳酸钠颗粒,在与洗涤剂组份混合贮存时,具有更高的活性氧稳定性。
因此,本发明涉及一种涂敷的过碳酸钠颗粒,它包含核和涂层,其核基本上为过碳酸钠,涂层至少含一种含过氧的硼化合物,其特征在于,从四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应得到的一种或多种反应产物用做含过氧的硼化合物。
涂敷颗粒的核基本上由过碳酸钠组成。“基本上”意味着过碳酸钠中还可能含有生产过程中加入的其它组成,例如苏打和少量的氯化钠以及结晶抑制剂,如偏磷酸盐或多羧酸以及常用的稳定剂,如镁盐和硅酸钠。术语“基本上”也意指过碳酸钠已经具有稳定组分涂层,例如膦酸盐、磷酸盐、苏打、水玻璃、镁盐、氨基羧酸盐和氨基膦酸盐以及羟基羧酸盐(hydroxycarboxylates)聚合物中任一种。一般来讲,已提出的任何涂敷组分甚至都可以是常见的硼化合物,尽管在要生产低硼含量的、涂敷的过碳酸钠颗粒的场合下,这看来是不适当的。
本发明方法中使用的过碳酸钠已经可以用标准方法生产。标准生产方法尤其包括所谓的湿法,其中苏打和过氧x氢在水相中发生反应,随后过碳酸钠结晶;以及所谓的喷淋法,其中含苏打及过氧化氢的水溶液喷淋到流化床干燥塔中的过碳酸钠颗粒上;还有所谓的干法,其中过氧化氢浓溶液与无水苏打反应。如果需要,标准生产方法之后还有标准涂敷方法。
按照本发明,涂敷的过碳酸钠颗粒中起稳定作用的壳层内含过氧化物的反应产物,该产物来源于四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液的反应,并且在与涂敷过碳酸钠颗粒相应的标准干燥条件下部分或全部地除去了水份。干燥及除水阶段可能伴随着熔融过程。
至今仍不知道生成的含过氧的硼化合物是否是过氧化氢与四硼酸盐或五硼酸盐的纯加合物。或含—B—O—O—H或—B—O—O—B—结构单元的化合物。甚至有可能含过氧的四或五硼酸盐在与生产相关的干燥过程中经历了部分的歧化过程,因此硼酸和从所谓的一水过硼酸钠中了解到的含结构单元的过硼酸盐可能在涂层中同时存在。
根据Ullmann’s Encyclopedia of Industrial Chemistry,5thEdition(1985),Vol.A4,270,用于形成上述含过氧的硼化合物的四硼酸盐和五硼酸盐具有以下阴离子结构:
四硼酸盐和五硼酸盐含有锂、钠或钾阳离子,优选钠阳离子。
优选的涂敷的过碳酸钠颗粒含通式为:Na2B4O7·nH2O2·mH2O的所谓的过四硼酸钠,其中n是1到4的整数,m是0到9的整数,做为涂层中的含过氧的硼化合物。优选每摩尔四硼酸盐结合2到4摩尔过氧化氢和0到2摩尔水。在特别优选的实施方案中,涂层基本上是Na2B4O7·4H2O2。
除了依照本发明的含过氧的硼化合物,尤其是相应的通式为Na2B4O7·4H2O2的过四硼酸钠外,涂层还可以含有均匀分布的其它已知起稳定作用的涂敷组分,如前面提到的那些稳定剂。如果需要,本发明中涂层外还可以包敷有其它几层含除本发明中使用的含过氧的硼化合物之外的其它稳定剂的涂层,以及非必须地包敷有含通用洗涤剂和清洁剂组合物中各组分如沸石的涂层。另外的这些涂层可以通过标准方法,尤其是通过喷淋、混合及造粒过程涂敷到根据本发明涂敷的过碳酸钠颗粒上。
根据本发明涂敷的过碳酸钠颗粒的涂敷量范围很宽,尽管按过碳酸钠计,1~30wt%的涂层量都可行,但实际证明使用1~10wt%,优选2~6wt%的涂敷量更有利。一方面,这些限定量的涂敷物提供给过碳酸钠以足够的稳定性以抵抗在潮湿环境中在与通常的洗涤剂、清洁剂和漂白剂组合物混合贮存时活性氧的损失;另一方面,涂敷的过碳酸钠的硼含量保持在低水平。
正如已经提到的,根据本发明的过碳酸钠颗粒的单层或多层涂层中可以含有除过氧化氢与四硼酸酸或五硼酸盐反应的产物之外的其它涂敷组分。有利的是,整个涂层含大于50wt%,尤其是大于70wt%的前面提到的过氧化氢与四硼酸盐或五硼酸盐的反应产物和小于50wt%,尤其是小于30wt%的其它稳定化合物。根据本发明涂敷的具有单涂层的过碳酸钠颗粒,该涂层基本上是本发明中使用的含过氧的硼化合物,在洗涤剂塔粉(Tower Powder)存在时表现出非常高的贮存稳定性,这种稳定剂是仅使用标准的过硼酸盐所达不到的,尽管硼含量保持一样。这点令人十分惊奇,因为分子式为Na2B4O7·4H2O2的过四硼酸钠不如一水过硼酸钠这么稳定。
根据本发明涂敷的过硼酸钠颗粒可以用以下方法制备,将至少一种含过氧的硼化合物和,如果需要,其它涂敷组分、优选使用其水溶液,涂敷到基本上为过碳酸钠的颗粒上,以及如果需要,再干燥生成的湿颗粒。该方法的特征在于,一种或多种由四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液得到的反应产物用做含过氧的硼化合物。
涂敷组分优选以其水溶液的形式涂敷到过碳酸钠颗粒上。从四硼酸盐或五硼酸盐与过氧化氢反应得到的反应混合物最好直接使用。
如果需要,含活性氧的硼化合物可以从反应混合物中回收,即将反应混合物溶液进一步浓缩或者甚至是部分或完全蒸发掉存在的水份使之成为固体,并且可以就这样用于本发明方法中。反应混合物最好照此方法直接制备以使含过氧的硼化合物保持所需的浓度。由于四硼酸盐或五硼酸盐与过氧化氢的反应产物其溶解度高,可以获得高浓度的含过氧的硼化合物溶液。这类溶液的好处在于,当它们通过喷淋嘴喷洒到过碳酸钠颗粒上时,不会产生喷嘴堵塞,因此不会出现故障。同时,在干燥过程中只需除去少量的水份。在制备这种反应混合物时,反应物的使用量要保证硼与活性氧的原子比为1∶0.2到1∶1.5。但优选硼与活性氧的原子比为1∶0.5到1∶1.25,尤其优选其原子比为1∶1或1:基本为1。在一特别优选的实施方案中,涂敷的过碳酸钠颗粒上的溶液含通式为Na2B4O7·nH2O2的过四硼酸钠,其中n为1到4的整数,优选2到4,更优选约为4的整数。在使用含Na2B4O7·4H2O2的溶液的场合下,如果溶液中另含有少量过量过氧化氢,使硼原子与活性氧的原子比约为1∶1.05~1.15,则是有利的。通过搅拌将四硼酸钠加入到过氧化氢水溶液中,很容易就得到了这种溶液。用这种方法可制备含有例如20~50wt%,尤其是25~40wt%的分子式为Na2B4O7·nH2O2的过四硼酸钠溶液,其中n为2到4的整数,用于本发明的方法。
本发明方法中使用的含过氧的硼化合物可以使用标准方法一步或分几步以连续或间断的方式涂敷到主要成份为过碳酸钠的颗粒上。待涂颗粒可以是干燥的或含有生产过程中残留的水份的过碳酸钠。因此,甚至可以使用如离心含水的或部分干燥的过碳酸钠。根据本发明涂敷的过碳酸钠颗粒可以通过将表面含水的过碳酸钠与粉末状的过四硼酸钠混合来制备,如果需要,随后进行干燥。但更有利的是将涂层组分溶液涂敷到过碳酸钠颗粒上。合适的方法有:例如,将溶液喷淋到颗粒上,同时进行混合;合适的混合器有:例如喷淋混合器如转筒、滚桶混合器、盘式造粒机等。在上述实施方案的替换实施方案中,湿法生产的过碳酸钠用本发明中的含过氧的硼化合物水溶液处理,该过程在如固/液分离器的清洗装置中进行,除去过量的溶液后,所得产物进行干燥。该实施方案相当于迄今尚未出版的德国专利申请书P4306399·3中的实施方案,不同的是在较早的申请书的方法中,使用了含过硼酸钠(NaBO2·H2O2)的溶液。在本发明的一特别优选的实施方案中,将水溶液喷洒在流化床中处于流化状态的待涂颗粒上。被喷洒的溶液加湿的颗粒同时或随后被干燥。如果使用流化床装置,通入加热到干燥温度的流化空气,可以同时进行喷淋和干燥。
含有依照本发明使用的含过氧的硼化合物及非必须的其它涂敷组分的溶液在喷淋过程中的温度可以是室温或直到约60℃的温度。在使用浓度特别高的溶液的场合下,最好将其加热,优选加热至30~50℃。在使用的溶液是通过四硼酸盐或五硼酸盐与过氧化氢反应得到的场合下,该溶液即将使用前的温度受着溶解热与反应热的影响大约位于所述的范围内。代替从反应物制备该溶液,该溶液也可以通过用水溶解经验式为Na2B4O7·4H2O2的过四硼酸钠来制备,正如DE—PS 548432中描述的;室温下1升水中可溶解过四硼酸钠达1kg。
用喷淋法获得的的湿的涂敷的过碳酸钠在通常干燥过碳酸钠的条件下进行干燥。因此,干燥温度在30~90℃范围内,优选50~80℃,更优选50~70℃。干燥温度应理解为待干燥颗粒的温度。因此,在一特别优选的实施方案中,该过程在流化床干燥器中进行的场合下,流化床温度在上述温度范围内。因此进入流化床干燥塔的干燥空气的温度高于流化床温度。
根据本发明涂敷的过碳酸钠颗粒可以做洗涤剂、清洁剂和漂白剂组合物中的漂白组份。根据本发明涂敷的过碳酸钠颗粒的突出优点是,其中的过碳酸钠具有意想不到的高贮存稳定性,因此通常条件下在这些组合物的贮存期间,活性氧的损失十分缓慢。在涂敷物用量相当及起始Oa含量高的情况下,所述组合物中根据本发明涂敷的过碳酸钠的贮存稳定性超过已知的其它涂敷过碳酸钠的水平。
含有根据本发明涂敷的过碳酸钠的洗涤剂、清洁剂和漂白剂组合物中,1~99wt%为该涂敷过碳酸钠,剩余的(配平至100wt%)为该组合物中常用的其它组份。虽然洗涤剂中过碳酸钠含量一般不超过20wt%,但漂白剂和清洁剂组合物中的过碳酸钠含量可以高得多。
含有根据本发明的涂敷的过碳酸钠的洗涤剂、清洁剂和漂白剂组合物中除上述的活性氧化合物之外,还含有一般浓度的其它常用组份。所述的其它组份特别包括以下成份:1.阳离子型、阴离子型、非离子型或两性表面活性剂;2.无机和/或有机增洁剂,其主要功能是螯合或络合影响水硬度的金属离子,例如沸石、多磷酸盐、氨基多乙酸和氨基多膦酸和聚羟羧酸;3.碱和无机电解质,如链烷醇胺和硅酸盐、碳酸盐和硫酸盐;4.N—酰基化合物和O—酰基化合物类的漂白活性剂,如;四乙酰乙二胺;5.组合物可能含的其它组分是:过氧化物稳定剂(尤其是镁盐)、污垢再沉积抑制剂、光亮剂、消泡剂、酶、消毒剂、防腐蚀剂、香料、染料和PH值调节剂、1到5类中各化合物的特例可以在DE—OS3321082的14—30页上到找到。
本发明涂敷的过碳酸钠颗粒在单独贮存或与洗涤剂、清洁剂和漂白组合物混合贮存时都表现出惊人的活性氧稳定性。仅使用过碳酸钠百分之儿的涂敷物量就能获得这种惊人的稳定程度。虽然知道硼酸、硼酸盐和过硼酸钠作涂敷组分是十分有效的,但本发明中优选的含过氧硼的化合物的有效性超过上述已知的硼化合物的有效性。本发明方法的实施十分简单:由于本发明中使用的过四硼酸钠和其它含过氧的硼化合物的溶解度很高,一步即可得到有效的涂层。另外,也不存在喷嘴阻塞产生的故障。干燥的耗能也保持很低的水平。
本发明通过以下实施例来说明。实施例1
通过苏打与过氧化氢在水相中反应得到的活性氧(Oa)含量为14.2wt%的过碳酸钠在一混合器内用含有通式为Na2B4O7·4H2O2的过四硼酸钠的溶液涂敷:
该涂敷溶液用以下步骤制备:将100.2g四硼酸钠(Na2B4O7·10H2O)溶于115.4g 35wt%的过氧化氢水溶液中,并加以搅拌及自生缓慢加热。该溶液含41wt%的Na2B4O7·4H2O和2.2wt%的H2O2。溶液中硼与活性氧的原子比为1∶1.13。
在实验用犁式混合器内将183g上述溶液喷洒到1500g过碳酸钠上,湿产品在流化床干燥塔内60℃下进行干燥。
涂敷过碳酰钠的Oa含量为14.4wt%;硼含量为0.61wt%,数据由Na2B4O7·4H2O2的使用量并以涂敷的过碳酸钠为基础计算的。表中列出涂敷的过碳酸钠加入到工业用含沸石的洗涤剂塔粉(Persil Supra TP)(其中15wt%为涂敷的过碳酸钠,85wt%为塔粉)后,在潮湿环境中混合物在洗涤剂包中贮存时的Oa稳定性。实施例2
在流化床干燥塔中将含过四硼酸钠(Na2B4O7·4H2O2)的溶液喷涂到过碳酸钠(依照实施例1)上,同时进行干燥。
该溶液是将四硼酸钠溶于19.5wt%的H2O2溶液而制得。Na2B4O7·4H2O2含量为31.2wt%;硼与活性氧的原子比为1∶1。将该溶液在50℃流化床温度下(干燥气体的入口温度110℃)通过一双组份喷嘴喷涂到过碳酸盐上。喷涂量为每100g份重过碳酸钠使用5份重过四硼酸钠;涂敷的过碳酸钠中的Oa含量为14.2wt%。表中列出了添加到粉状洗涤剂中的过碳酸钠Oa稳定性(塔粉和混合比同实施例1)。实施例3
重复实施例2,但不同的是喷涂溶液含分子式为Na2B4O7·2H2O2的过四硼酸钠;其含量为28.7wt%;硼与活性氧的原子比为1∶1。
涂敷量为过碳酸钠量的5wt%。涂敷过碳酸钠中的Oa含量为14.0wt%。洗涤剂塔粉中Oa稳定性也列于表中(塔粉和混合比同实施例1)。实施例4
离心含水的过碳酸钠(通过在水相在氯化钠及六偏磷酸钠存在下苏打与过氧化氢反应并结晶而制得)在离心机中后处理,即除去母液后用过四硼酸钠溶液(Na2B4O7·4H2O2的33wt%)洗涤,随后在流化床干燥塔中干燥。Na2B4O7·4H2O2的涂敷量为过碳酸钠的2.5wt%。硼含量约为0.3wt%。涂敷过碳酸钠的Oa含量为14.2wt%。其贮存稳定性列于表中。比较实施例1
使用DE—PS 2800916中的方法(见该说明书的实施例A6)用5wt%的原硼酸涂敷过碳酸钠。该涂敷的过碳酸钠的Oa含量为13.4wt%;硼含量为涂敷的过碳酸钠的0.83wt%。在洗涤剂混合物中贮存时的稳定性数据列于表中。比较实施例2
在一混合器内(同实施例1)将四硼酸钠水溶液(浓度为35wt%)喷涂到过碳酸钠上,每100份重过碳酸钠喷涂四硼酸钠的数量为5份重。所得物随后在70℃下进行干燥。
Oa含量为13.5wt%;涂敷的过碳酸盐中硼含量为0.55wt%,数据由涂敷的四硼酸钠计算出,其中假设干燥过程中四硼酸钠转化成Na2B4O7·5H2O。比较实施例3
依照DE—PS 2810379,用过硼酸钠和水玻璃涂敷的过碳酸钠。涂敷量为6wt%的一水过硼酸钠和1wt%水玻璃。涂敷的过碳酸钠的Oa含量为14.3wt%;硼含量为0.62wt%(数据由涂敷的NaBO2·H2O2量计算出)。在洗涤剂组合物中的稳定性数据列于表中。
为了估价稳定性,上述实施例及比较实施例中涂敷的过碳酸钠与工业用无磷酸盐但含沸石的洗涤剂塔粉(Persil Supra TP)混合(混合比为15∶85)后贮存于密封的洗涤剂包装袋中(0.4l),置于恒温30℃、相对湿度为80%的气候试验箱中。贮存开始及贮存2、4和8周后,以一般方法对混合物中的活性氧进行了测定,测定结果列于表中。对于几乎相同的硼含量来说,依照本发明涂敷的过碳酸钠颗粒显示了比用硼酸、四硼酸钠或一水过硼酸盐涂敷的过碳酸钠颗粒有更高的贮存稳定性。
表 贮存稳定性
实施例号 | 涂敷物量(wt%) | 涂敷的过碳酸钠的堆积密度(克/升) | 在洗涤剂组合物中过碳酸钠的绝对Oa含量(wt%) | 8周后Oa剩余量(%) | |||
开始 | 2周 | 4周 | 8周 | ||||
1234比较实施例CE 1CE 2CE 3 | Na2B4O7·4 H2O25%Na2B4O7·4 H2O25%Na2B4O7·2 H2O25%Na2B4O7·4 H2O22.5%B(OH)35%Na2B4O7·1O H2O5%NaBO2·H2O26% | 1050970990920970960940 | 14.414.214.014.213.413.514.3 | 13.813.913.313.912.712.313.3 | 13.712.612.912.811.311.912.8 | 12.511.511.210.98.39.610.0 | 86.880.98076.761.97170 |
Claims (10)
1.包含一种核和一种涂层的、涂敷的过碳酸钠颗粒,其核基本上为过碳酸钠且其涂层含有至少一种含过氧的硼化合物,其特征在于,由四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应的一种或多种反应产物为该含过氧的硼化合物。
2.根据权利要求1的涂敷的过碳酸钠颗粒,其特征在于,涂层中的含过氧的硼化合物是通式为Na2B4O7·nH2O2·mH2O的过四硼酸钠,其中n为1到4,优选2到4的整数;m为0到9,优选0到2的整数。
3.根据权利要求1或2的、涂敷的过碳酸钠颗粒,其特征在于,涂层量为过碳酸钠的1~10wt%,优选2~6wt%。
4.根据权利要求1到3的、涂敷的过碳酸钠颗粒,其特征在于,涂层含大于50wt%、优选大干70wt%的过氧化氢与四硼酸盐或五硼酸盐的反应产物及小于50wt%、优选小于30wt%的其它起稳定作用的化合物。
5.一种生产包含一种核和一种涂层的、涂敷的过碳酸钠颗粒的方法,该颗粒的核基本上是过碳酸钠,涂层含有一种或多种涂敷组分,其中包含至少一种含过氧的硼化合物,该方法包括,将至少一种含过氧的硼化合物和,如果需要,其它涂敷组分、优选以其水溶液形式,涂敷到基本上为过碳酸钠的颗粒上,如果需要的话,干燥其湿颗粒,该法的特征在于,由四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应的一种或多种反应产物作为该含过氧的硼化合物。
6.根据权利要求5的方法,其特征在于,所述的反应产物以其水溶液形式使用,优选以反应混合物的水溶液形式使用,所述的溶液含有硼和活性氧,其硼与活性氧的原子比为1∶0.2到1∶1.5,优选1∶0.5到1∶1.25,更优选的为1:实质上的1。
7.根据权利要求5或6的方法,其特征在于,涂敷的溶液含通式为Na2B4O7·nH2O2的过四硼酸钠,其中n为1到4的整数,优选2到4的整数。
8.根据权利要求5至7任一项的方法,其特征在于,涂敷的溶液含20~50wt%、尤其是25~40wt%通式为Na2B4O7·nH2O2的过四硼酸钠,其中n为2到4的整数,尤其是4。
9.根据权利要求5至8中任一项的方法,其特征在于,在一混合器或流化床干燥塔中将含过氧的硼化合物的水溶液喷涂到主要成份为过碳酸钠的颗粒上,得到的湿颗粒同时或随后在30~90℃、优选50~80℃下进行干燥。
10.含有根据权利要求1至3或根据权利要求4至9的方法制得的、涂敷的过碳酸钠颗粒的洗涤剂、清洁剂和漂白剂组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4311944.1 | 1993-04-10 | ||
DE4311944A DE4311944A1 (de) | 1993-04-10 | 1993-04-10 | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1120832A true CN1120832A (zh) | 1996-04-17 |
Family
ID=6485306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94191734A Pending CN1120832A (zh) | 1993-04-10 | 1994-02-28 | 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5658873A (zh) |
EP (1) | EP0693039B1 (zh) |
JP (1) | JP3599737B2 (zh) |
KR (1) | KR100308473B1 (zh) |
CN (1) | CN1120832A (zh) |
AT (1) | ATE156096T1 (zh) |
AU (1) | AU6207894A (zh) |
CA (1) | CA2159991A1 (zh) |
CZ (1) | CZ249895A3 (zh) |
DE (2) | DE4311944A1 (zh) |
ES (1) | ES2106515T3 (zh) |
FI (1) | FI954808A0 (zh) |
PL (1) | PL173925B1 (zh) |
SI (1) | SI9400166A (zh) |
TR (1) | TR27402A (zh) |
TW (1) | TW265320B (zh) |
WO (1) | WO1994024044A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101270232B (zh) * | 2008-04-22 | 2011-04-20 | 浙江时代金科过氧化物有限公司 | 一种颗粒型包膜过碳酸钠的制备方法 |
Families Citing this family (539)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
EP0728139B1 (en) | 1993-09-03 | 2003-08-13 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
DE4439069A1 (de) * | 1994-11-02 | 1996-05-09 | Degussa | Percarbonathaltige Wasch-, Bleich- und Reinigungsmittelzusammensetzung |
DE19629381A1 (de) * | 1996-07-20 | 1998-01-22 | Eilenburger Elektrolyse & Umwelttechnik Gmbh | Granulierter Aktivsauerstoffträger |
DE19544293C2 (de) * | 1995-11-28 | 1998-01-29 | Degussa | Umhüllte Natriumpercarbonatpartikel und deren Verwendung |
DE19600018A1 (de) | 1996-01-03 | 1997-07-10 | Henkel Kgaa | Waschmittel mit bestimmten oxidierten Oligosacchariden |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
EP1012331B1 (en) | 1997-07-01 | 2006-03-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
FR2768140B1 (fr) * | 1997-09-05 | 1999-10-08 | Atochem Elf Sa | Solution sursaturee stable de perborate de sodium et son application dans la fabrication des particules de percarbonate de sodium stabilisees |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
EP1080103A4 (en) | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES |
AU753270B2 (en) | 1998-05-21 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6335439B1 (en) | 1998-06-11 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Method of preparing phosphoramidites |
US6225293B1 (en) | 1998-09-02 | 2001-05-01 | Isis Pharmaceuticals, Inc. | Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations |
WO2000017309A1 (en) * | 1998-09-23 | 2000-03-30 | The Procter & Gamble Company | Coated perborate bleach and compositions containing the same |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6300320B1 (en) | 1999-01-05 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Modulation of c-jun using inhibitors of protein kinase C |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6617442B1 (en) * | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP1127840A1 (en) * | 2000-02-21 | 2001-08-29 | SOLVAY & Cie (Société Anonyme) | Process for preparing coated alkali metal percarbonate, coated alkaki metal percarbonate obtainable by this process, its use in detergent compositions, and detergent compositions containing it |
DE60140864D1 (de) * | 2000-04-13 | 2010-02-04 | Thomas N Wight | Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican |
KR100366556B1 (ko) | 2000-04-26 | 2003-01-09 | 동양화학공업주식회사 | 세제용 입상 코티드 과탄산나트륨과 이의 제조방법 |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
EP2336166A1 (en) | 2000-10-12 | 2011-06-22 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US6573051B2 (en) * | 2001-03-09 | 2003-06-03 | Molecular Staging, Inc. | Open circle probes with intramolecular stem structures |
ES2328796T3 (es) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | Interaccion tsg101-gag y uso de la misma. |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
CA2633171C (en) | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
AU2002315393A1 (en) | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
DE60238143D1 (de) | 2001-09-18 | 2010-12-09 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
NZ577565A (en) | 2001-10-09 | 2010-10-29 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US20030170678A1 (en) * | 2001-10-25 | 2003-09-11 | Neurogenetics, Inc. | Genetic markers for Alzheimer's disease and methods using the same |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
WO2003057160A2 (en) | 2002-01-02 | 2003-07-17 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7169916B2 (en) * | 2002-04-01 | 2007-01-30 | Isis Pharmaceuticals, Inc. | Chloral-free DCA in oligonucleotide synthesis |
MXPA04010092A (es) | 2002-04-16 | 2004-12-13 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
AU2003276131A1 (en) * | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
US20050287648A1 (en) | 2002-08-05 | 2005-12-29 | University Of Rochester | Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof |
CN1694959B (zh) | 2002-09-13 | 2013-09-18 | 雷普利瑟公司 | 非序列互补的抗病毒寡核苷酸 |
EP1546170A4 (en) * | 2002-09-20 | 2007-08-29 | Univ Yale | RIBOSWITCHS, METHODS OF USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES |
EP1549767A4 (en) | 2002-09-26 | 2006-06-07 | Amgen Inc | MODULATION OF FORKHEAD BOX O1A GENE EXPRESSION |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
ES2420914T3 (es) | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Modulación antisentido de la expresión de la apolipoproteína B |
EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
US7754450B2 (en) | 2002-11-15 | 2010-07-13 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
JP4915980B2 (ja) | 2002-11-15 | 2012-04-11 | エムユーエスシー ファウンデーション フォー リサーチ デベロップメント | 補体レセプター2標的化補体調節因子 |
EP1624753B1 (en) | 2002-11-21 | 2012-01-25 | The University of Utah Research Foundation | Purinergic modulation of smell |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US20040121338A1 (en) * | 2002-12-19 | 2004-06-24 | Alsmadi Osama A. | Real-time detection of rolling circle amplification products |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
WO2004058987A2 (en) | 2002-12-20 | 2004-07-15 | Qiagen Gmbh | Nucleic acid amplification |
ES2400033T3 (es) | 2003-02-11 | 2013-04-05 | Antisense Therapeutics Ltd | Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina |
US7002006B2 (en) * | 2003-02-12 | 2006-02-21 | Isis Pharmaceuticals, Inc. | Protection of nucleosides |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
BRPI0410886A (pt) | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único |
EP1633770B1 (en) | 2003-06-13 | 2015-04-29 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
US7790691B2 (en) | 2003-06-20 | 2010-09-07 | Isis Pharmaceuticals, Inc. | Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
US7425544B2 (en) | 2003-09-18 | 2008-09-16 | Eli Lilly And Company | Modulation of eIF4E expression |
WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8790919B2 (en) | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
US20050267300A1 (en) | 2004-04-05 | 2005-12-01 | Muthiah Manoharan | Processes and reagents for oligonucleotide synthesis and purification |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
EP3225633B1 (en) | 2004-05-21 | 2020-03-25 | The UAB Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7427675B2 (en) * | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
WO2006032144A1 (en) | 2004-09-23 | 2006-03-30 | Arc Pharmaceuticals, Inc. | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources |
JP2008516991A (ja) | 2004-10-20 | 2008-05-22 | アンチセンス セラピューティクス リミテッド | インテグリンα4発現のアンチセンス調節 |
US20060105937A1 (en) * | 2004-11-15 | 2006-05-18 | Melani Hardt Duran | Aqueous cleaning composition |
WO2006063031A2 (en) * | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
CN101175769A (zh) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | 用于调控血管完整性的方法和组合物 |
US8309303B2 (en) | 2005-04-01 | 2012-11-13 | Qiagen Gmbh | Reverse transcription and amplification of RNA with simultaneous degradation of DNA |
GB0508622D0 (en) * | 2005-04-28 | 2005-06-08 | Probe Ind Ltd | Method for treating effluent |
EP1891141B1 (en) | 2005-05-31 | 2016-11-16 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US7776532B2 (en) | 2005-08-11 | 2010-08-17 | Synthetic Genomics, Inc. | Method for in vitro recombination |
JP2009504168A (ja) | 2005-08-17 | 2009-02-05 | メディクシス エス.エー. | Ck19発現を確認する組成物及び方法 |
WO2007027775A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
EP1762627A1 (de) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2392645A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
JP5111385B2 (ja) * | 2005-10-28 | 2013-01-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ハンチンチン遺伝子の発現を抑制するための組成物および方法 |
CA2626584A1 (en) * | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
AU2006311730B2 (en) | 2005-11-09 | 2010-12-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor V Leiden mutant gene |
JP2009516710A (ja) | 2005-11-21 | 2009-04-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | eIF4E−BP2の発現のモジュレート |
JP2009524411A (ja) * | 2005-12-21 | 2009-07-02 | イェール ユニバーシティー | リボスイッチの調節に関連した方法および組成物 |
JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードrna転写物 |
EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
EP2527354A1 (en) | 2006-03-31 | 2012-11-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
MX2008014005A (es) | 2006-05-03 | 2009-01-27 | Baltic Technology Dev Ltd | Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial. |
EP2505650A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PCSK9 |
US8586554B2 (en) | 2006-05-05 | 2013-11-19 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PTP1B |
DK2066684T3 (da) * | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
US7666854B2 (en) * | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
CA2652770A1 (en) | 2006-05-19 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of aha and therapeutic uses thereof |
WO2007137220A2 (en) | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
US9506056B2 (en) | 2006-06-08 | 2016-11-29 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
US8101585B2 (en) * | 2006-08-04 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of JNK proteins |
US20100137440A1 (en) * | 2006-09-11 | 2010-06-03 | Yale University | Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches |
US7947487B2 (en) | 2006-10-05 | 2011-05-24 | Massachusetts Institute Of Technology | Multifunctional encoded particles for high-throughput analysis |
ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
US8084437B2 (en) * | 2006-11-27 | 2011-12-27 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
KR20090089462A (ko) | 2006-12-11 | 2009-08-21 | 유니버시티 오브 유타 리써치 파운데이션 | 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법 |
US20100129358A1 (en) | 2006-12-22 | 2010-05-27 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
KR101488800B1 (ko) | 2007-02-09 | 2015-02-04 | 노오쓰웨스턴 유니버시티 | 세포내 타겟 검출용 입자 |
JP2010520749A (ja) * | 2007-02-27 | 2010-06-17 | ノースウェスタン ユニバーシティ | ナノ粒子への分子の結合 |
CN101801185A (zh) | 2007-03-22 | 2010-08-11 | 耶鲁大学 | 与控制可变剪接的核糖开关有关的方法和组合物 |
AU2008232891B2 (en) | 2007-03-29 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the Ebola |
US20110091377A1 (en) | 2007-05-11 | 2011-04-21 | The Johns Hopkins University | Biomarkers for melanoma |
CA2687684A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | Methods and compositions related to riboswitches that control alternative splicing and rna processing |
SG174103A1 (en) * | 2007-05-29 | 2011-09-29 | Univ Yale | Riboswitches and methods and compositions for use of and with riboswitches |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
US7807372B2 (en) * | 2007-06-04 | 2010-10-05 | Northwestern University | Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
EP2176280B2 (en) * | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
US8088904B2 (en) | 2007-08-15 | 2012-01-03 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
JP2010538005A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
WO2009039466A1 (en) | 2007-09-20 | 2009-03-26 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
WO2009039442A1 (en) | 2007-09-21 | 2009-03-26 | California Institute Of Technology | Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
EP2222851B1 (en) | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
JP5530933B2 (ja) | 2007-12-10 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 第vii因子遺伝子発現阻害のための組成物及び方法 |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
EA019531B1 (ru) | 2008-03-05 | 2014-04-30 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ Eg5 И VEGF |
WO2009124238A1 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
WO2009124295A2 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
JP5685182B2 (ja) | 2008-04-18 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 初発自己免疫性糖尿病を予防するため、および/または逆転させるためのマイクロスフェアに基づく組成物 |
EP2280995A2 (en) * | 2008-04-29 | 2011-02-09 | Wyeth LLC | Methods for treating inflammation |
EP2297322A1 (en) | 2008-06-04 | 2011-03-23 | The Board of Regents of The University of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
EP2334319B1 (en) | 2008-08-25 | 2017-12-06 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2331690B1 (en) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of mutant egfr gene |
US20100075883A1 (en) * | 2008-09-24 | 2010-03-25 | Ecolab Inc. | Granular cleaning and disinfecting composition |
US8501805B2 (en) * | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
EP2334793B1 (en) | 2008-09-25 | 2016-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of serum amyloid a gene |
EP2743265B1 (en) | 2008-10-09 | 2017-03-15 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
IL302142B1 (en) | 2008-10-20 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Compounds and methods for inhibiting transthyretin expression |
EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
DK2365803T3 (en) | 2008-11-24 | 2018-01-22 | Univ Northwestern | POLYVALENT RNA NANOPARTICLE COMPOSITIONS |
CN102317458B (zh) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
EP2370580B1 (en) | 2008-12-04 | 2019-09-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
KR101546673B1 (ko) * | 2009-01-15 | 2015-08-25 | 삼성전자주식회사 | 전자 사진용 토너 및 그의 제조방법 |
WO2010088537A2 (en) | 2009-01-29 | 2010-08-05 | Alnylam Pharmaceuticals, Inc. | Improved lipid formulation |
US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
JP5766126B2 (ja) | 2009-02-12 | 2015-08-19 | クルナ・インコーポレーテッド | 脳由来神経栄養因子(bdnf)関連疾病の、bdnfに対する天然アンチセンス転写物の抑制による治療 |
CA2752239C (en) | 2009-02-12 | 2021-03-30 | Opko Curna, Llc | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
EP2403946A4 (en) | 2009-03-04 | 2012-11-14 | TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1 | |
US20100267806A1 (en) | 2009-03-12 | 2010-10-21 | David Bumcrot | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
CN102482677B (zh) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病 |
CN102549159B (zh) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | 通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病 |
CA2757694C (en) | 2009-04-15 | 2020-10-06 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
EP2421972A2 (en) | 2009-04-24 | 2012-02-29 | The Board of Regents of The University of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
DK2424987T3 (en) | 2009-05-01 | 2018-02-26 | Curna Inc | TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG |
AU2010245933B2 (en) | 2009-05-05 | 2016-06-16 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
NZ596186A (en) | 2009-05-05 | 2014-03-28 | Alnylam Pharmaceuticals Inc | Lipid compositions |
ES2609655T3 (es) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010132665A1 (en) | 2009-05-15 | 2010-11-18 | Yale University | Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
ES2618576T3 (es) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico |
HUE038796T2 (hu) | 2009-06-10 | 2018-11-28 | Arbutus Biopharma Corp | Továbbfejlesztett lipid készítmény |
JP6128846B2 (ja) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CN106983768B (zh) | 2009-06-17 | 2023-04-07 | 冷泉港实验室 | 用于在对象中调节smn2剪接的组合物和方法 |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2464336A4 (en) | 2009-08-14 | 2013-11-20 | Alnylam Pharmaceuticals Inc | COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE |
WO2011022420A1 (en) | 2009-08-17 | 2011-02-24 | Yale University | Methylation biomarkers and methods of use |
KR101892760B1 (ko) | 2009-08-25 | 2018-08-28 | 큐알엔에이, 인크. | IQGAP에 대한 천연 안티센스 전사체의 억제에 의한 GTPase 활성화 단백질을 함유하는 IQ 모티프(IQGAP)와 관련된 질환의 치료 |
AU2010289400B2 (en) | 2009-09-02 | 2014-10-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
CA2778442A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
JP6147502B2 (ja) | 2009-10-27 | 2017-06-14 | スウィフト バイオサイエンシーズ, インコーポレイテッド | ポリヌクレオチドプライマー及びプローブ |
US9376690B2 (en) | 2009-10-30 | 2016-06-28 | Northwestern University | Templated nanoconjugates |
WO2011053994A1 (en) | 2009-11-02 | 2011-05-05 | Alnylam Pharmaceuticals, Inc. | Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
KR20120102674A (ko) | 2009-11-03 | 2012-09-18 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 중합체 분석물을 검출하는 다용도의 가시적인 방법 |
CA2781469A1 (en) | 2009-11-23 | 2011-05-26 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
CN102741294A (zh) | 2009-11-30 | 2012-10-17 | 霍夫曼-拉罗奇有限公司 | 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体 |
NO2513310T3 (zh) | 2009-12-16 | 2018-03-31 | ||
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
KR101853508B1 (ko) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | 종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
WO2011085347A2 (en) | 2010-01-11 | 2011-07-14 | Opko Curna, Llc | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
WO2011088076A2 (en) | 2010-01-12 | 2011-07-21 | Yale University | Structured rna motifs and compounds and methods for their use |
BR112012017483A2 (pt) * | 2010-01-14 | 2019-09-24 | Haplomics Inc | previsão e redução de aloimunogenicidade de terapêuticos de proteína |
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
CA2824843A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
PE20130214A1 (es) | 2010-02-23 | 2013-03-11 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
AU2011235276B2 (en) | 2010-03-29 | 2015-09-03 | Alnylam Pharmaceuticals, Inc. | SiRNA therapy for transthyretin (TTR) related ocular amyloidosis |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
US20110269194A1 (en) | 2010-04-20 | 2011-11-03 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
MX343559B (es) | 2010-04-29 | 2016-11-10 | Ionis Pharmaceuticals Inc | Modulacion de la expresion de transtiretina. |
CN107988228B (zh) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
MX342239B (es) | 2010-05-03 | 2016-09-21 | Genentech Inc * | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
US20130203045A1 (en) | 2010-05-26 | 2013-08-08 | University Of Virginia Patent Foundation | Method for detecting nucleic acids based on aggregate formation |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
EP2576579B1 (en) | 2010-06-02 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
CA2802049C (en) | 2010-06-07 | 2018-07-10 | Firefly Bioworks, Inc. | Scanning multifunctional particles |
US9638632B2 (en) | 2010-06-11 | 2017-05-02 | Vanderbilt University | Multiplexed interferometric detection system and method |
WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
NO2593547T3 (zh) | 2010-07-14 | 2018-04-14 | ||
US20130143955A1 (en) | 2010-08-09 | 2013-06-06 | Yale University | Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
RU2624048C2 (ru) | 2010-10-06 | 2017-06-30 | Курна, Инк. | Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4 |
JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療 |
KR101913232B1 (ko) | 2010-10-27 | 2018-10-30 | 큐알엔에이, 인크. | 인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료 |
CN110123830A (zh) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法 |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
US9127275B2 (en) | 2010-12-10 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
EP2670404B1 (en) | 2011-02-02 | 2018-08-29 | The Trustees of Princeton University | Sirtuin modulators as virus production modulators |
MX365647B (es) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas. |
MY165507A (en) | 2011-02-03 | 2018-03-28 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
KR102365961B1 (ko) | 2011-03-29 | 2022-02-23 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
EP2694660B1 (en) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
CN103620036B (zh) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
CA3191066A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
AU2012272970A1 (en) | 2011-06-21 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
EP2723351B1 (en) | 2011-06-21 | 2018-02-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP2723390B1 (en) | 2011-06-23 | 2017-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
JP2014526887A (ja) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 造血幹細胞移植の成功率を改善する方法 |
EP4269584A3 (en) | 2011-08-11 | 2024-03-27 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
US9580713B2 (en) | 2011-09-17 | 2017-02-28 | Yale University | Fluoride-responsive riboswitches, fluoride transporters, and methods of use |
RS57645B1 (sr) | 2011-10-14 | 2018-11-30 | Hoffmann La Roche | Anti-htra1 antitela i načini primene |
CA2859387A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013106358A1 (en) | 2012-01-10 | 2013-07-18 | Hussain M Mahmood | Method of treating hyperlipidemia and atherosclerosis with mir-30c |
JP6509723B2 (ja) | 2012-03-13 | 2019-05-08 | スウィフト バイオサイエンシーズ, インコーポレイテッド | 核酸ポリメラーゼによる基質ポリヌクレオチドの大きさ制御されたホモポリマーテーリングのための方法および組成物 |
ES2694592T3 (es) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
US9610362B2 (en) | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US9914922B2 (en) | 2012-04-20 | 2018-03-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
US20140038182A1 (en) | 2012-07-17 | 2014-02-06 | Dna Logix, Inc. | Cooperative primers, probes, and applications thereof |
EP2897633B1 (en) | 2012-09-18 | 2020-01-01 | UTI Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
WO2014089541A2 (en) | 2012-12-07 | 2014-06-12 | Haplomics, Inc. | Factor viii mutation repair and tolerance induction |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
US10398661B2 (en) | 2013-02-28 | 2019-09-03 | The Board Of Regents Of The University Of Texas System | Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
PT2970974T (pt) | 2013-03-14 | 2017-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de componente do complemento c5 e métodos para a sua utilização |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP4286517A3 (en) | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US10590412B2 (en) | 2013-04-19 | 2020-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
SG10201804472YA (en) | 2013-05-22 | 2018-07-30 | Alnylam Pharmaceuticals Inc | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
SG11201510565TA (en) | 2013-05-22 | 2016-01-28 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
EP3004396B1 (en) | 2013-06-06 | 2019-10-16 | The General Hospital Corporation | Compositions for the treatment of cancer |
ES2862125T3 (es) | 2013-06-13 | 2021-10-07 | Antisense Therapeutics Ltd | Terapia combinada para acromegalia |
LT3019619T (lt) | 2013-07-11 | 2021-12-10 | Modernatx, Inc. | Sintetinius polinukleotidus apimančios kompozicijos, koduojančios susijusius su crispr baltymus ir sintetines sgrnas, ir jų naudojimo būdai |
HUE048710T2 (hu) | 2013-08-08 | 2020-08-28 | Scripps Research Inst | Eljárás nukleinsavak in vitro helyspecifikus enzimes jelölésére nem-természetes nukleotidok beépítésével |
EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10077444B2 (en) | 2013-10-02 | 2018-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
LT3052628T (lt) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Kompozicijos ir būdai alas1 geno raiškai nuslopinti |
EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
EP3060680B1 (en) | 2013-10-21 | 2019-02-27 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
WO2015066708A1 (en) | 2013-11-04 | 2015-05-07 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna) |
US10182988B2 (en) | 2013-12-03 | 2019-01-22 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US10385388B2 (en) | 2013-12-06 | 2019-08-20 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
EP3798306A1 (en) | 2013-12-12 | 2021-03-31 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
US10900083B2 (en) | 2013-12-20 | 2021-01-26 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
JP6736467B2 (ja) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | 平滑化変異体及びその使用方法 |
KR20230152154A (ko) | 2014-02-11 | 2023-11-02 | 알닐람 파마슈티칼스 인코포레이티드 | 케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법 |
EP3943607A1 (en) | 2014-04-09 | 2022-01-26 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
MA39835A (fr) | 2014-04-17 | 2017-02-22 | Biogen Ma Inc | Compositions et procédés de modulation de l'épissage du smn2 chez un patient |
TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療serpinc1相關疾患之方法和組成物 |
SG10202104570TA (en) | 2014-05-22 | 2021-06-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
AU2015270925A1 (en) | 2014-06-02 | 2016-12-22 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3155100B1 (en) | 2014-06-10 | 2021-12-22 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US9951327B1 (en) | 2014-07-17 | 2018-04-24 | Integrated Dna Technologies, Inc. | Efficient and rapid method for assembling and cloning double-stranded DNA fragments |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
JP7081923B2 (ja) | 2014-07-31 | 2022-06-07 | ユーエイビー リサーチ ファンデーション | アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果 |
CA2958431A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
ES2928500T3 (es) | 2014-08-29 | 2022-11-18 | Alnylam Pharmaceuticals Inc | Patisirán para su uso en el tratamiento de amiloidosis mediada por transtiretina |
EP4043567A1 (en) | 2014-08-29 | 2022-08-17 | Children's Medical Center Corporation | Methods and compositions for the treatment of cancer |
EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
EP3194597B1 (en) | 2014-09-18 | 2021-06-30 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
EP3904519A1 (en) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
MX2017006139A (es) | 2014-11-10 | 2017-11-16 | Glaxosmithkline Intelectual Property (No 2) Ltd | Composiciones farmaceuticas de accion prolongada para hepatitis c. |
SG11201703646SA (en) | 2014-11-10 | 2017-06-29 | Glaxosmithkline Intellectual Property (No 2) Ltd | Combination long acting compositions and methods for hepatitis c |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US20160145547A1 (en) | 2014-11-25 | 2016-05-26 | Milliken & Company | Film-Encased Cleaning Composition |
EP3234141A4 (en) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
WO2016118812A1 (en) | 2015-01-23 | 2016-07-28 | Vanderbilt University | A robust interferometer and methods of using same |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
KR20180020125A (ko) | 2015-03-27 | 2018-02-27 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
CA3205381A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
SG10202007937SA (en) | 2015-09-02 | 2020-09-29 | Alnylam Pharmaceuticals Inc | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
PE20181009A1 (es) | 2015-10-30 | 2018-06-26 | Genentech Inc | ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS |
ES2938883T3 (es) | 2015-11-05 | 2023-04-17 | Los Angeles Childrens Hospital | Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda |
US10993995B2 (en) | 2015-12-07 | 2021-05-04 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
US10627396B2 (en) | 2016-01-29 | 2020-04-21 | Vanderbilt University | Free-solution response function interferometry |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
HUE060123T2 (hu) | 2016-06-24 | 2023-01-28 | Scripps Research Inst | Új nukleozid-trifoszfát-transzporter és alkalmazásai |
CN109844103A (zh) | 2016-07-21 | 2019-06-04 | 美克斯细胞有限公司 | 用于修饰基因组dna的方法和组合物 |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
AU2017376950B2 (en) | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
SG11201905508VA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hsd17b13 variants and uses thereof |
WO2018183969A1 (en) | 2017-03-30 | 2018-10-04 | California Institute Of Technology | Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform |
TWI801377B (zh) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | 治療具有b型肝炎病毒(hbv)感染之個體之方法 |
AU2018300069A1 (en) | 2017-07-11 | 2020-02-27 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
JP7277432B2 (ja) | 2017-07-13 | 2023-05-19 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法 |
US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
KR20200089656A (ko) | 2017-09-19 | 2020-07-27 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법 |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
EP3714054A1 (en) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
BR112020012088A2 (pt) | 2017-12-18 | 2020-11-17 | Alnylam Pharmaceuticals, Inc. | composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos |
WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
CA3091857A1 (en) | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
AU2019247490A1 (en) | 2018-04-06 | 2020-10-22 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
AU2019266207A1 (en) | 2018-05-07 | 2020-12-17 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
TW202016304A (zh) | 2018-05-14 | 2020-05-01 | 美商阿尼拉製藥公司 | 血管收縮素原(AGT)iRNA組成物及其使用方法 |
EA202190528A1 (ru) | 2018-08-13 | 2021-04-23 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
US20210348162A1 (en) | 2018-08-16 | 2021-11-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
US20220056220A1 (en) | 2018-09-14 | 2022-02-24 | Northwestern University | Programming protein polymerization with dna |
WO2020060986A1 (en) | 2018-09-18 | 2020-03-26 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP3856907A1 (en) | 2018-09-28 | 2021-08-04 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
WO2020118259A1 (en) | 2018-12-06 | 2020-06-11 | Northwestern University | Protein crystal engineering through dna hybridization interactions |
CN113631709A (zh) | 2018-12-20 | 2021-11-09 | 普拉克西斯精密药物股份有限公司 | 用于治疗kcnt1相关病症的组合物和方法 |
HRP20231338T1 (hr) | 2018-12-20 | 2024-02-16 | Vir Biotechnology, Inc. | Kombinirana terapija hbv |
MX2021008628A (es) | 2019-01-16 | 2021-11-17 | Genzyme Corp | Composiciones de arni para serpinc1 y metodos de uso de las mismas. |
MX2021009259A (es) | 2019-02-06 | 2021-08-24 | Synthorx Inc | Conjugados de il-2 y metodos de uso del mismo. |
US20220339256A1 (en) | 2019-05-13 | 2022-10-27 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus (hbv) infection |
US20220211743A1 (en) | 2019-05-17 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
JP2022538784A (ja) | 2019-06-14 | 2022-09-06 | ザ スクリプス リサーチ インスティテュート | 半合成生物における複製、転写および翻訳のための試薬ならびに方法 |
WO2021022109A1 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
WO2021030706A1 (en) | 2019-08-15 | 2021-02-18 | Synthorx, Inc. | Immuno oncology combination therapies with il-2 conjugates |
CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
MX2022002689A (es) | 2019-09-03 | 2022-04-07 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2). |
KR20220061158A (ko) | 2019-09-10 | 2022-05-12 | 신톡스, 인크. | 자가면역질환을 치료하기 위한 il-2 접합체 및 사용 방법 |
EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
EP4045652A1 (en) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
EP4048793A1 (en) | 2019-10-22 | 2022-08-31 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
AR120341A1 (es) | 2019-11-01 | 2022-02-09 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO |
MX2022005251A (es) | 2019-11-04 | 2022-06-08 | Synthorx Inc | Conjugados de interleuquina 10 y sus usos. |
EP4055165A1 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
JP2023500681A (ja) | 2019-11-06 | 2023-01-10 | アルニラム ファーマスーティカルズ インコーポレイテッド | 肝臓外送達 |
EP4061945A1 (en) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US20230057461A1 (en) | 2020-01-27 | 2023-02-23 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Rab13 and net1 antisense oligonucleotides to treat metastatic cancer |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
CA3170377A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
CN115397989A (zh) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021178736A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
CN116209759A (zh) | 2020-03-26 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | 冠状病毒iRNA组合物及其使用方法 |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
BR112022020145A2 (pt) | 2020-04-06 | 2023-01-03 | Alnylam Pharmaceuticals Inc | Composições e métodos para silenciamento da expressão de myoc |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
KR20230018377A (ko) | 2020-04-27 | 2023-02-07 | 알닐람 파마슈티칼스 인코포레이티드 | 아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법 |
KR20230017789A (ko) | 2020-04-30 | 2023-02-06 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법 |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
CA3162416C (en) | 2020-05-15 | 2023-07-04 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
EP4150090A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
EP4161552A1 (en) | 2020-06-05 | 2023-04-12 | The Broad Institute, Inc. | Compositions and methods for treating neoplasia |
EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
CN116209760A (zh) | 2020-06-18 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | 黄嘌呤脱氢酶(XDH)iRNA组合物及其使用方法 |
BR112022026316A2 (pt) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos |
TW202216203A (zh) | 2020-06-25 | 2022-05-01 | 美商欣爍克斯公司 | Il-2接合物及抗egfr抗體之免疫腫瘤學組合治療 |
US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
TW202229552A (zh) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法 |
MX2023004032A (es) | 2020-10-09 | 2023-04-27 | Synthorx Inc | Terapias inmuno-oncologicas con conjugados de il-2. |
MX2023004029A (es) | 2020-10-09 | 2023-04-27 | Synthorx Inc | Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab. |
EP4232581A1 (en) | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
JP2023549500A (ja) | 2020-11-13 | 2023-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 凝固第V因子(F5)iRNA組成物およびその使用方法 |
TW202237150A (zh) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | 用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物 |
EP4259795A1 (en) | 2020-12-08 | 2023-10-18 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
WO2022147214A2 (en) | 2020-12-31 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
TW202245843A (zh) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法 |
EP4291243A1 (en) | 2021-02-12 | 2023-12-20 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
JP2024509783A (ja) | 2021-02-25 | 2024-03-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | プリオンタンパク質(prnp)irna組成物およびその使用方法 |
WO2022182574A1 (en) | 2021-02-26 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
EP4304640A1 (en) | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
CA3214499A1 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
KR20240009393A (ko) | 2021-03-31 | 2024-01-22 | 엔트라다 테라퓨틱스, 인크. | 사이클릭 세포 침투 펩티드 |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
EP4330392A1 (en) | 2021-04-26 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022235537A1 (en) | 2021-05-03 | 2022-11-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis |
AU2022271873A1 (en) | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
WO2022240760A2 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING |
WO2022240721A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2022256395A1 (en) | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
TW202313679A (zh) | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法 |
BR112023025224A2 (pt) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos |
WO2022260939A2 (en) | 2021-06-08 | 2022-12-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders |
IL309001A (en) | 2021-06-23 | 2024-02-01 | Entrada Therapeutics Inc | Antisense compounds and methods for targeting CUG repeats |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
KR20240036041A (ko) | 2021-07-21 | 2024-03-19 | 알닐람 파마슈티칼스 인코포레이티드 | 대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법 |
IL309905A (en) | 2021-07-23 | 2024-03-01 | Alnylam Pharmaceuticals Inc | IRNA compositions in β-catenin (CTNNB1) and methods of using them |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
CN117795074A (zh) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | 转甲状腺素蛋白(TTR)iRNA组合物和其使用方法 |
TW202337474A (zh) | 2021-08-04 | 2023-10-01 | 美商艾拉倫製藥股份有限公司 | 用於緘默血管收縮素原(AGT)的iRNA組成物及方法 |
AR126771A1 (es) | 2021-08-13 | 2023-11-15 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA EL FACTOR XII (F12) Y SUS MÉTODOS DE USO |
CA3229661A1 (en) | 2021-09-01 | 2023-03-09 | Xiang Li | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
WO2023044094A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
WO2023064530A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
TW202334418A (zh) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓(HTT)iRNA劑組成物及其使用方法 |
WO2023092060A1 (en) | 2021-11-18 | 2023-05-25 | Cornell University | Microrna-dependent mrna switches for tissue-specific mrna-based therapies |
WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1978953A (en) * | 1928-10-17 | 1934-10-30 | Du Pont | Method of preparing an alkali metal perborate |
DE548432C (de) * | 1928-10-17 | 1932-04-12 | Degussa | Herstellung eines Perborates |
US3327684A (en) * | 1963-03-11 | 1967-06-27 | Fairchild Camera Instr Co | Masking apparatus for spray coating |
FR2226460B1 (zh) * | 1973-04-20 | 1976-12-17 | Interox | |
JPS5315717B2 (zh) * | 1973-12-20 | 1978-05-26 | ||
DE2652776A1 (de) * | 1975-05-13 | 1978-05-24 | Interox Chemicals Ltd | Verfahren zur herstellung von natriumpercarbonat |
LU72575A1 (zh) * | 1975-05-23 | 1977-02-10 | ||
DE2810379C3 (de) * | 1978-03-10 | 1980-12-11 | Degussa Ag, 6000 Frankfurt | Verfahren zur Herstellung von stabilisiertem Natriumpercarbonat |
DE2651442C3 (de) * | 1976-11-11 | 1979-11-15 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Natriumpercarbonat-Partikel |
US4156039A (en) * | 1976-11-11 | 1979-05-22 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler | Sodium percarbonate particles (A) |
DE2712139C3 (de) * | 1977-03-19 | 1982-05-19 | Degussa Ag, 6000 Frankfurt | Natriumpercarbonat-Schichtpartikel |
LU76548A1 (zh) * | 1977-01-10 | 1978-09-18 | ||
DE2800760C2 (de) * | 1978-01-09 | 1983-01-27 | Degussa Ag, 6000 Frankfurt | Verfahren zur Herstellung von Natriumpercarbonat aus einer Sodalösung bzw. -suspension |
GB1575792A (en) * | 1978-01-10 | 1980-10-01 | Interox | Peroxygen compounds |
DE3321082C2 (de) * | 1982-06-10 | 1996-08-22 | Kao Corp | Bleich-Reinigungsmittel |
GB2123044B (en) * | 1982-06-10 | 1986-02-05 | Kao Corp | Bleaching detergent composition |
EP0117578A3 (en) * | 1983-02-23 | 1985-01-30 | Shionogi & Co., Ltd. | Azole-substituted alcohol derivatives |
US4952232A (en) * | 1987-04-29 | 1990-08-28 | E. I. Du Pont De Nemours And Company | Antifungal carbinols |
DE3784787T2 (de) * | 1986-06-23 | 1994-01-20 | Du Pont Merck Pharma | Fungizide Karbinole. |
DE3720277A1 (de) * | 1987-06-19 | 1988-12-29 | Degussa | Verfahren zur verminderung der neigung zum zusammenbacken von teilchenfoermigen aktivsauerstoffverbindungen |
DE3813874A1 (de) * | 1987-07-10 | 1989-01-19 | Bayer Ag | Hydroxyalkyl-azolyl-derivate |
DE3921481A1 (de) * | 1989-06-30 | 1991-01-03 | Bayer Ag | Hydroxyethyl-cyclopropyl-azolyl-derivate |
WO1991012000A1 (en) * | 1990-02-13 | 1991-08-22 | E.I. Du Pont De Nemours And Company | ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS |
JP2636496B2 (ja) * | 1990-11-21 | 1997-07-30 | 花王 株式会社 | 安定な過炭酸ソーダ粒子及びその製造法 |
-
1993
- 1993-04-10 DE DE4311944A patent/DE4311944A1/de not_active Withdrawn
-
1994
- 1994-02-28 AT AT94909085T patent/ATE156096T1/de active
- 1994-02-28 ES ES94909085T patent/ES2106515T3/es not_active Expired - Lifetime
- 1994-02-28 PL PL94311035A patent/PL173925B1/pl unknown
- 1994-02-28 CN CN94191734A patent/CN1120832A/zh active Pending
- 1994-02-28 AU AU62078/94A patent/AU6207894A/en not_active Abandoned
- 1994-02-28 KR KR1019950704418A patent/KR100308473B1/ko not_active IP Right Cessation
- 1994-02-28 CZ CZ952498A patent/CZ249895A3/cs unknown
- 1994-02-28 JP JP52265894A patent/JP3599737B2/ja not_active Expired - Fee Related
- 1994-02-28 US US08/525,782 patent/US5658873A/en not_active Expired - Lifetime
- 1994-02-28 EP EP94909085A patent/EP0693039B1/de not_active Expired - Lifetime
- 1994-02-28 CA CA002159991A patent/CA2159991A1/en not_active Abandoned
- 1994-02-28 DE DE59403562T patent/DE59403562D1/de not_active Expired - Lifetime
- 1994-02-28 TW TW083101684A patent/TW265320B/zh active
- 1994-02-28 WO PCT/EP1994/000576 patent/WO1994024044A1/de not_active Application Discontinuation
- 1994-04-04 TR TR00294/94A patent/TR27402A/xx unknown
- 1994-04-07 SI SI9400166A patent/SI9400166A/sl unknown
-
1995
- 1995-10-09 FI FI954808A patent/FI954808A0/fi unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101270232B (zh) * | 2008-04-22 | 2011-04-20 | 浙江时代金科过氧化物有限公司 | 一种颗粒型包膜过碳酸钠的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2159991A1 (en) | 1994-10-27 |
TR27402A (tr) | 1995-02-28 |
FI954808A (fi) | 1995-10-09 |
EP0693039B1 (de) | 1997-07-30 |
ATE156096T1 (de) | 1997-08-15 |
CZ249895A3 (en) | 1996-04-17 |
TW265320B (zh) | 1995-12-11 |
WO1994024044A1 (de) | 1994-10-27 |
PL173925B1 (pl) | 1998-05-29 |
US5658873A (en) | 1997-08-19 |
KR960701801A (ko) | 1996-03-28 |
JPH08508707A (ja) | 1996-09-17 |
DE4311944A1 (de) | 1994-10-13 |
PL311035A1 (en) | 1996-01-22 |
FI954808A0 (fi) | 1995-10-09 |
ES2106515T3 (es) | 1997-11-01 |
EP0693039A1 (de) | 1996-01-24 |
KR100308473B1 (ko) | 2002-07-02 |
JP3599737B2 (ja) | 2004-12-08 |
AU6207894A (en) | 1994-11-08 |
DE59403562D1 (de) | 1997-09-04 |
SI9400166A (en) | 1994-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1120832A (zh) | 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 | |
US3951838A (en) | Silica sol stabilizers for improving the stability of sodium percarbonate in solid bleaches and detergents | |
US3977988A (en) | Stabilized sodium percarbonate and process for preparing same | |
KR101434347B1 (ko) | 코팅된 과탄산나트륨 입자 | |
CA2108513C (en) | Sodium percarbonate stabilized by coating | |
US20060014658A1 (en) | Sodium percarbonate particles with improved storage stability | |
PL186136B1 (pl) | Kompozycja detergentowa zawierająca nadwęglan sodu | |
RU2136584C1 (ru) | Способ стабилизации частиц перкарбоната щелочного металла | |
EP0675851B1 (en) | Process for stabilising alkali percarbonate particles, particles obtained thereby and washing and/or bleaching compositions containing them | |
CN1056586C (zh) | 加以包覆的碱金属过酸盐及其制备方法 | |
KR20090035546A (ko) | 코팅된 과탄산나트륨 입자 | |
JPH07509268A (ja) | 洗剤組成物 | |
CN1054353C (zh) | 稳定粒状碱金属过碳酸盐的方法 | |
JPH0437119B2 (zh) | ||
JPH0640709A (ja) | 安定な過炭酸ソーダ及びその製造法並びに安定な過炭酸ソーダを含有する漂白洗浄剤組成物 | |
JP2869310B2 (ja) | 安定な過炭酸ソーダ及びその製造方法並びに安定な過炭酸ソーダを含有してなる漂白洗浄剤組成物 | |
US5670470A (en) | Percarbonate stabilised by coating with an aqueous solution of phosphate and boron compounds | |
US20010048911A1 (en) | Process for preparing a stabilized sodium carbonate peroxyhydrate | |
JPH0352795B2 (zh) | ||
WO1995005341A2 (en) | Oxidising bleach | |
US5744055A (en) | Stable monopersulfate triple salt and its method of preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |